CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- 8-K Event Executive or director change
- 4 Planned sale Chief Accounting Officer sold 105,000 shares at an average $30.34 ($3,185,656)
- 4 Planned sale Chief Accounting Officer sold 40,000 shares at an average $30.20 ($1,208,159)
- S-8 Other Securities Offered to Employees in Benefit Plans
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Executive or director change · Shareholder vote results
- 4 Planned sale Chief Accounting Officer sold 65,000 shares at $35.69 ($2,319,850)
- 144 Insider Sale of Securities
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- 8-K Event Executive or director change
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Open-market sale Director sold 44,619 shares at an average $30.42 ($1,357,230)
- 144 Insider Sale of Securities
- 4 Open-market sale Director sold 28,186 shares at $29.41 ($828,950)
- 4 Planned sale Chief Scientific Officer sold 300,000 shares at an average $30.30 ($9,090,868)
Page 2 of 21 · 415 filings